Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes

Figures & data

Table 1 Approved Targeted Agents in the Systemic Treatment of DTC

Treatment	Molecular Target	Clinical Trial ID(s)
Lenvatinib	Multikinase inhibitor (VEGFR1–3, FGFR 1–4, PDGFRα, c-KIT, RET)	NCT01321554
Sorafenib	Multikinase inhibitor (VEGFR2–3, PDGFRβ, RAF)	NCT00984282
Sunitinib	Multikinase inhibitor (PDGFRα, β, VEGFR1–3, c-KIT, CSF-1R, FLT-3, RET)	NCT00668811
Axitinib	Multikinase inhibitor (VEGFR1–3, PDGFR, c-KIT)	NCT00828919
Everolimus	Multikinase inhibitor (mTOR, HIF-1)	NCT01118065
Vandetanib	Multikinase inhibitor (EGFR, VEGFR, RET, BRK, TIE-2, EPH, Src)	NCT01876784
Cabozantinib	Multikinase inhibitor (RET, MET, VEGRF1–3, KIT, FLT-3, AXL, TIE-2)	NCT03690388
Pazopanib	Multikinase inhibitor (VEGFR1–3, PDGFRα, β, FGFR1&3, c-KIT, ltk, Lck, c-Fms)	NCT00625846
Vemurafenib	BRAF	NCT01286753
Dabrafenib	(BRAF, CRAF)	NCT01723202
Larotrectinib	NTRK1–3	NCT02122913;NCT02637687; NCT02576431
Entrectinib	NTRK1–3, some ROS1, ALK	EudraCT2012–000148-88; NCT02097810; NCT02568267
Selpercatinib	RET	NCT03157128
Pralsetinib	RET	NCT03037385
Pembrolizumab	PD-1	NCT02973997

Table 2 Ongoing Clinical Trials with Cabozantinib in Thyroid Cancer

Treatment	Indication	Trial Status	Clinical Trial ID
Cabozantinib vs placebo after VEGF therapy	RAI-R DTC	Active,not recruiting	NCT03690388
Cabozantinib	RAI-R DTC	Active,not recruiting	NCT02041260
Cabozantinib, nivolumab, and Ipilimumab after VEGF therapy	RAI-R DTC	Active,not recruiting	NCT03914300
Cabozantinib vs Lenvatinib	Metastatic endocrine cancers (including DTC)	Active,not recruiting	NCT02592356
Cabozantinib plus atezolizumab	LA or metastatic tumors (including DTC)	Active,not recruiting	NCT03170960
Cabozantinib plus atezolizumab	Advanced endocrine cancers (including DTC)	Recruiting	NCT04400474
Cabozantinib plus nivolumab	Advanced cancer (including DTC) and HIV	Recruiting	NCT04514484
Two doses of cabozantinib (60 vs 140 mg)	Metastatic MTC	Active,not recruiting	NCT01896479
Cabozantinib	Young patients with R/M rare tumors (including MTC)	Active,not recruiting	NCT02867592